{"id":12751,"date":"2026-05-28T22:06:00","date_gmt":"2026-05-28T20:06:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=db1209504dfc70051f08ac1c2eb87724"},"modified":"2026-05-28T22:06:00","modified_gmt":"2026-05-28T20:06:00","slug":"abionyx-pharma-provides-an-update-on-its-operations-and-cash-position-for-the-first-quarter-of-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12751","title":{"rendered":"ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<b>Consolidated revenue of \u20ac0.8 million as of the end of March 2026 and \u20ac2.6 million secured for the year<\/b><\/li>\n<li>\n<b>Cash position of \u20ac2.8 million as of March 31, 2026, stable compared to December 31, 2025, before receipt of \u20ac0.7 million in research tax credits<\/b><\/li>\n<li>\n<b>Financial visibility horizon extended to the end of 2028 given the funding 100% secured from the capital increase with maintenance of preemptive subscription rights and the non-dilutive loan announced on May 27<\/b><\/li>\n<\/ul><p>TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:<\/p><p>\n<b>ABIONYX Pharma, (FR0012616852 \u2013 ABNX \u2013 PEA PME eligible)<\/b>, a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today provides an update on its business and cash and cash equivalents as of March 31, 2026.<\/p><p>\nABIONYX Pharma recorded consolidated revenue of \u20ac0.8 million for the first quarter of 2026, a slight decrease compared to the first quarter of 2025. Thanks to its strong technological differentiation in this non-strategic business, the Company enjoys good commercial visibility for the current fiscal year, with \u20ac2.6 million in business already secured as of the end of May.<\/p><p>\nRegarding its core strategic business dedicated to the development of innovative therapies aimed at improving patients\u2019 lives, the Company did not generate revenue during the quarter, as ABIONYX Pharma continues to provide its bioproduct free of charge in connection with applications for Compassionate Use Authorization (AAC).<\/p><p>\nAs of March 31, 2026, ABIONYX Pharma had cash reserves of \u20ac2.8 million, a level equivalent to that of December 31, 2025, and prior to the receipt of Research Tax Credits estimated at approximately \u20ac0.7 million.<\/p><p>\n<b>Outlook:<\/b><\/p><p>\nABIONYX Pharma notes that on May 27, 2026, it announced the launch of a \u20ac18.7 million capital increase with shareholders\u2019 preemptive subscription rights, which is 100% secured and coupled with the establishment of a non-dilutive bond financing of \u20ac10 million, which may be increased to \u20ac14 million. These transactions will significantly strengthen the Company\u2019s financial resources and extend its financial visibility horizon through the end of 2028.<\/p><p>\nThis 100% secured financing will enable ABIONYX Pharma to achieve several key milestones in its development, notably the submission of the marketing authorization application for CER-001 in the orphan indication of LCAT deficiency, as well as the full funding of the Phase 2b clinical trial in sepsis, the third leading cause of death worldwide and for which no approved treatment is available, despite a significant unmet medical need.<\/p><p>\n<b>Selected Financial Information (IFRS)<\/b><\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>\u20acM<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Q1 2026<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Q1 2025<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Biotech revenue<\/b><\/p><\/td><td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n0.00<\/p><\/td><td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n0.00<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>IRIS Pharma revenue<\/b><\/p><\/td><td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n0.83<\/p><\/td><td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n0.99<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Total revenue<\/b><\/p><\/td><td class=\"bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>0.83<\/b><\/p><\/td><td class=\"bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>0.99<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl3 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Other revenue and operating income<\/i><\/p><\/td><td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n0.00<\/p><\/td><td class=\"bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n0.00<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwrowaltcolor0 bwpadl0 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Total revenue and operating income<\/b><\/p><\/td><td class=\"bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>0.83<\/b><\/p><\/td><td class=\"bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>0.99<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth76\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Cash and cash equivalents at the end of the period<\/b><\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>2.83<\/b><\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>4.09<\/b><\/p><\/td><\/tr>\n<\/table><p>\n<b><span class=\"bwuline\">Next financial release:<\/span><\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Cash position and Q2 2026 business update<\/b>, August 27, 2026<\/li>\n<\/ul><p>\n<b>About ABIONYX Pharma<\/b><\/p><p>\nABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and critical care, developing breakthrough biotherapies for serious conditions for which there are no effective treatments. Through its proprietary apoA-I-based technology platform, ABIONYX Pharma designs innovative biologics and next-generation HDL carriers that target the immune-inflammatory dysregulation at the core of sepsis and other severe diseases. Driven by recognized scientific expertise, a differentiated pipeline, and an expanding global clinical network, ABIONYX Pharma aims to redefine therapeutic standards for sepsis and become a key player in intensive care.<\/p><p>\n<i><span class=\"bwuline\">Disclaimer:<\/span><\/i><\/p><p>\n<i>The statements contained in this document may constitute \u201cforward-looking statements.\u201d These statements include all matters that are not historical facts and can generally, but not always, be identified by the use of words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cshould,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201cis expected to,\u201d \u201cwill continue,\u201d \u201cmay,\u201d \u201cis likely to,\u201d \u201cforecasts,\u201d or similar expressions, including their variations and negative forms or comparable terms.<\/i><\/p><p>\n<i>Forward-looking statements are not guarantees of future performance; they involve a number of known and unknown risks, uncertainties, and other factors, and ABIONYX Pharma\u2019s actual operating results, financial condition, and the development of the sector in which it operates may differ materially from those indicated or suggested in the forward-looking statements contained in this document. Furthermore, even if ABIONYX Pharma\u2019s operating results and financial condition, as well as developments in the sector in which it operates, are consistent with the forward-looking statements contained in this document, such results or developments are not necessarily indicative of results or developments in subsequent periods. ABIONYX Pharma does not undertake to publicly update or revise any forward-looking statements that may be made in this document, whether as a result of new information, future events, or otherwise.<\/i><\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ABIONYX Pharma<\/b><br\/><a  href=\"mailto:infos@abionyx.com\" rel=\"nofollow\" shape=\"rect\">infos@abionyx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Consolidated revenue of \u20ac0.8 million as of the end of March 2026 and \u20ac2.6 million secured for the year<\/p>\n<p>Cash position of \u20ac2.8 million as of March 31, 2026, stable compared to December 31, 2025, before receipt of \u20ac0.7 million in research tax credits<\/p>\n<p>&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12751","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12751"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12751\/revisions"}],"predecessor-version":[{"id":12752,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12751\/revisions\/12752"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}